Naltrexone controlled-release - TheraKine

Drug Profile

Naltrexone controlled-release - TheraKine

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Rainbow Biosciences; TheraKine
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alcoholism; Opioid abuse

Most Recent Events

  • 28 Jul 2016 BioCorRx in-licenses sustained release medication delivery technology from TheraKine
  • 03 Aug 2015 Naltrexone controlled-release - Rainbow BioSciences/TheraKine is available for licensing in USA as of 28 Jul 2015. www.rainbowbiosciences.com
  • 23 Jul 2015 Rainbow Biosciences and an undisclosed company signs a letter of intent for distribution of naltrexone in Canada before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top